Values First Advisors Inc. Has $925,000 Holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Values First Advisors Inc. lifted its stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 20.1% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 23,725 shares of the company’s stock after buying an additional 3,971 shares during the quarter. Values First Advisors Inc. owned about 0.05% of Mirum Pharmaceuticals worth $925,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Quest Partners LLC grew its position in Mirum Pharmaceuticals by 7,513.3% in the 2nd quarter. Quest Partners LLC now owns 1,142 shares of the company’s stock valued at $39,000 after purchasing an additional 1,127 shares during the period. Amalgamated Bank lifted its stake in Mirum Pharmaceuticals by 60.8% during the 2nd quarter. Amalgamated Bank now owns 1,357 shares of the company’s stock valued at $46,000 after acquiring an additional 513 shares in the last quarter. ProShare Advisors LLC bought a new position in Mirum Pharmaceuticals during the 2nd quarter valued at $213,000. Creative Planning bought a new stake in shares of Mirum Pharmaceuticals during the 3rd quarter worth $249,000. Finally, Arizona State Retirement System raised its stake in shares of Mirum Pharmaceuticals by 10.6% during the 2nd quarter. Arizona State Retirement System now owns 9,210 shares of the company’s stock worth $315,000 after purchasing an additional 883 shares during the period.

Analyst Ratings Changes

MIRM has been the topic of a number of recent analyst reports. Robert W. Baird lifted their target price on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Evercore ISI boosted their price objective on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Leerink Partners boosted their price objective on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a research note on Thursday, October 17th. HC Wainwright restated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Friday, October 11th. Finally, Cantor Fitzgerald boosted their price objective on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 8th. Ten analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $56.82.

Mirum Pharmaceuticals Stock Up 2.4 %

Shares of NASDAQ MIRM opened at $39.36 on Friday. The stock has a market capitalization of $1.86 billion, a P/E ratio of -10.61 and a beta of 1.14. Mirum Pharmaceuticals, Inc. has a one year low of $23.14 and a one year high of $45.23. The company has a debt-to-equity ratio of 1.34, a current ratio of 3.28 and a quick ratio of 3.09. The firm’s 50 day simple moving average is $40.42 and its two-hundred day simple moving average is $34.12.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 7th. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). The company had revenue of $77.90 million for the quarter, compared to analysts’ expectations of $75.03 million. Mirum Pharmaceuticals had a negative net margin of 40.34% and a negative return on equity of 43.47%. The business’s revenue for the quarter was up 107.7% compared to the same quarter last year. During the same period last year, the company posted ($0.92) EPS. As a group, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.75 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.